1. Home
  2. RTO vs EXAS Comparison

RTO vs EXAS Comparison

Compare RTO & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rentokil Initial plc

RTO

Rentokil Initial plc

HOLD

Current Price

$29.80

Market Cap

13.7B

ML Signal

HOLD

Logo Exact Sciences Corporation

EXAS

Exact Sciences Corporation

HOLD

Current Price

$101.43

Market Cap

11.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RTO
EXAS
Founded
1925
1995
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Business Services
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.7B
11.0B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RTO
EXAS
Price
$29.80
$101.43
Analyst Decision
Buy
Buy
Analyst Count
2
20
Target Price
N/A
$77.94
AVG Volume (30 Days)
677.3K
7.2M
Earning Date
01-21-2026
11-03-2025
Dividend Yield
1.72%
N/A
EPS Growth
N/A
N/A
EPS
0.13
N/A
Revenue
$7,581,860,530.00
$3,082,033,000.00
Revenue This Year
$48.64
$19.40
Revenue Next Year
$3.22
$13.51
P/E Ratio
$222.46
N/A
Revenue Growth
N/A
14.47
52 Week Low
$19.60
$38.81
52 Week High
$30.16
$102.66

Technical Indicators

Market Signals
Indicator
RTO
EXAS
Relative Strength Index (RSI) 67.39 86.97
Support Level $28.45 $101.30
Resistance Level $30.16 $101.93
Average True Range (ATR) 0.39 0.37
MACD 0.14 -1.35
Stochastic Oscillator 86.62 48.00

Price Performance

Historical Comparison
RTO
EXAS

About RTO Rentokil Initial plc

Rentokil Initial is the largest global provider of route-based pest control and commercial hygiene services, operating in 89 countries. The group also offers a range of specialist route-based services, including office and commercial space plant care, property care, and workwear rentals. The group serves a diverse client base of global food producers, hotel chains, industrial goods companies, restaurants, and individual residential customers.

About EXAS Exact Sciences Corporation

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Share on Social Networks: